In Brief
Refine Search
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biosimilars
Deficiencies identified by the US Food and Drug Administration (FDA) at Icelandic biosimilar firm Alvotech’s Reykjavik facility have resulted in a second complete response letter (CRL) for AVT02, its copy of Humira (adalimumab). 30 June 2023
Biotechnology
Dublin, Ireland-headquartered protein specialist Prothena has published results from the Phase III VITAL trial in a journal of the American Society of Hematology (ASH). 30 June 2023
Pharmaceutical
To ensure the effective implementation of India's National Rare Disease Policy-2021, the Delhi High Court has formed a five-member National Rare Diseases Committee to ensure that the policy benefits reach the ultimate patients. 30 June 2023
Biotechnology
Cancer giant Bristol Myers Squibb has secured a new European approval for its checkpoint blocker Opdivo (nivolumab), in non-small cell lung cancer (NSCLC). 30 June 2023
Pharmaceutical
Canada-headquartered Aurinia Pharmaceuticals saw its shares leap more than 17% to $10.77 in pre-market trading, after it said that its board of directors has initiated an exploration of strategic alternatives. 30 June 2023
Biotechnology
The US Food and Drug Administration yesterday approved Lantidra (donislecel), the first allogeneic (donor) pancreatic islet cellular therapy made from deceased donor pancreatic cells for the treatment of type 1 diabetes. 30 June 2023
Pharmaceutical
China's National Medical Products Administration (NMPA) has recently launched a nationwide drug safety consolidation and enhancement campaign to establish a solid foundation for drug safety. 30 June 2023
Biotechnology
US pharma major Eli Lilly is to acquire Sigilon Therapeutics, a biopharma company seeking to develop functional cures for patients with a range of acute and chronic diseases. 29 June 2023
Pharmaceutical
BioXcel has presented positive top-line results for TRANQUILITY II, a Phase III trial of BXCL501, its orally dissolving film formulation of dexmedetomidine under investigation for the acute treatment of Alzheimer’s disease-related agitation. 29 June 2023
Pharmaceutical
A decades-long program to develop the first new vaccine for pulmonary tuberculosis in a century has received a half-billion dollar funding boost. 29 June 2023
Biotechnology
Chinese biotech Laekna has listed on the main board of Hong Kong’s stock exchange. 29 June 2023
Pharmaceutical
Italy’s privately-held Italfarmaco Group has taken another pivotal step towards approval of its proprietary histone deacetylase (HDAC), givinostat, in Duchenne muscular dystrophy (DMD). 29 June 2023
Biotechnology
Lars Petersen has been named as the new president and chief executive officer (CEO) of FUJIFILM Diosynth Biotechnologies, a Japanese contract development and manufacturing organization (CDMO), and subsidiary of FUJIFILM Corp, effective immediately. 29 June 2023
Pharmaceutical
US clinical stage biotech RenovoRx saw its shares leap 30% to $2.90 in pre-market activity, after it released positive interim Phase III data showing an 8-month improvement in progression-free survival (PFS) for patients on RenovoGem (intra-arterial administration of gemcitabine) in locally advanced pancreatic cancer. 29 June 2023
Biotechnology
French pharma major Sanofi hosted a Vaccines Investor Event today, when it reaffirmed its ambition to deliver more than 10 billion euros ($10.9 billion) in annual vaccines sales by 2030, driven by core franchises of influenza, meningitis, and pediatric vaccines, with the addition of RSV. 29 June 2023
Pharmaceutical
An Expert View from Chris Blanchette, Novo Nordisk, Kathy Lang, PRECISIONheor, Ross Maclean, Precision Value & Health. 29 June 2023
Pharmaceutical
Traders have taken a downbeat view of Cognition Therapeutics’ prospects, with top-line results from a Phase II trial shaking confidence in the firm’s Alzheimer’s research. 29 June 2023
Pharmaceutical
The US Food and Drug Administration’s (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted in favor of investigational palovarotene as an effective treatment, with a positive risk-benefit profile, for people living with the ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP). 29 June 2023
Biotechnology
San Diego, USA-based biotech AvantGen has appointed of Jordon Wang as its new chief operating officer (COO) and senior vice president of technology development. 29 June 2023
Biotechnology
BlueRock Therapeutics, a wholly-owned subsidiary of German life sciences company Bayer, can boast that bemdaneprocel, its neuronal stem cell therapy for Parkinson’s disease, is the first to show positive results in a Phase I study. 28 June 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze